Rituximab Biosimilar – Anti-MS4A1 mAb – Research Grade

Reference:
Size

,

Isotype

IgG1

Brand

Product type

Clonality

Expression system

Applications

,

Product nameRituximab Biosimilar - Anti-MS4A1 mAb - Research Grade
SourceDrugBank DB00073
SpeciesHuman
Expression systemMammalian cells
Molecular weight143kDa
Purity>85%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°C)
Delivery lead time in business days3-5 days if in stock; 3-5 weeks if production needed
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
Aliases /SynonymsRituximab,Rituximab,MS4A1,anti-MS4A1
ReferencePX-TA1010
NoteFor research use only. Not suitable for human use.
IsotypeIgG1
ClonalityMonoclonal Antibody

Description of Rituximab Biosimilar - Anti-MS4A1 mAb - Research Grade

General information about Rituximab

Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death. Rituximab is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. This product is for research use only.

Publication

  • Rhomberg-Kauert J, Karlsson M, Thiagarajan D, Kallas T, Karlsson F, Fredriksson S, Dahlberg J and Martinez Barrio A (2024) Using adjusted local assortativity with Molecular Pixelation unveils colocalization of membrane proteins with immunological significance. Front. Immunol. 15:1309916. doi: 10.3389/fimmu.2024.1309916
  • Joshua S. Bray, Gethin R. Thomas, Victoria M. Smith, Sandrine Jayne, Martin J.S. Dyer, Harriet S. Walter, Comparative in-Vitro Efficacy of CD20xCD3 IgG Bispecific Biosimilar Constructs Against Diffuse Large B Cell Lymphoma (DLBCL) Cell Lines with Different Levels of Expression of CD20, Blood, Volume 144, Supplement 1, 2024, Page 5826, ISSN 0006-4971, https://doi.org/10.1182/blood-2024-203884.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Rituximab Biosimilar – Anti-MS4A1 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

CD20 Protein – Human CD20 Recombinant Protein
Antigen

CD20 Protein – Human CD20 Recombinant Protein

PX-P3060 210€
Anti-Rituximab Polyclonal Antibody
Polyclonal Antibody

Anti-Rituximab Polyclonal Antibody

PTX18872 650€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.






    Cart (0 Items)

    Your cart is currently empty.

    View Products